Literature DB >> 22750293

Developmental defects and rescue from glucose intolerance of a catalytically-inactive novel Ship2 mutant mouse.

Eléonore Dubois1, Monique Jacoby, Marianne Blockmans, Eileen Pernot, Serge N Schiffmann, Lazaros C Foukas, Jean-Claude Henquin, Bart Vanhaesebroeck, Christophe Erneux, Stéphane Schurmans.   

Abstract

The function of the phosphoinositide 5-phosphatase Ship2 was investigated in a new mouse model expressing a germline catalytically-inactive Ship2(∆/∆) mutant protein. Ship2(∆/∆) mice were viable with defects in somatic growth and in development of muscle, adipose tissue and female genital tract. Lipid metabolism and insulin secretion were also affected in these mice, but glucose tolerance, insulin sensitivity and insulin-induced PKB phosphorylation were not. We expected that the expression of the catalytically inactive Ship2 protein in PI 3'-kinase-defective p110α(D933A/+) mice would counterbalance the phenotypes of parental mice by restoring normal PKB signaling but, for most of the parameters tested, this was not the case. Indeed, often, the Ship2(∆/∆) phenotype had a dominant effect over the p110α(D933A/+) phenotype and, sometimes, there was a surprising additive effect of both mutations. p110α(D933A/+)Ship2(∆/∆) mice still displayed a reduced PKB phosphorylation in response to insulin, compared to wild type mice yet had a normal glucose tolerance and insulin sensitivity, like the Ship2(∆/∆) mice. Together, our results suggest that the Ship2(∆/∆) phenotype is not dependent on an overstimulated class I PI 3-kinase-PKB signaling pathway and thus, indirectly, that it may be more dependent on the lack of Ship2-produced phosphatidylinositol 3,4-bisphosphate and derived phosphoinositides.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22750293     DOI: 10.1016/j.cellsig.2012.06.012

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  10 in total

1.  Opsismodysplasia resulting from an insertion mutation in the SH2 domain, which destabilizes INPPL1.

Authors:  Bing Li; Deborah Krakow; Deborah A Nickerson; Michael J Bamshad; Yong Chang; Ralph S Lachman; Alev Yilmaz; Hülya Kayserili; Daniel H Cohn
Journal:  Am J Med Genet A       Date:  2014-06-20       Impact factor: 2.802

2.  A second locus for Schneckenbecken dysplasia identified by a mutation in the gene encoding inositol polyphosphate phosphatase-like 1 (INPPL1).

Authors:  Hane Lee; Lisette Nevarez; Ralph S Lachman; William R Wilcox; Deborah Krakow; Daniel H Cohn
Journal:  Am J Med Genet A       Date:  2015-05-22       Impact factor: 2.802

3.  Whole-genome analysis reveals that mutations in inositol polyphosphate phosphatase-like 1 cause opsismodysplasia.

Authors:  Jennifer E Below; Dawn L Earl; Kathryn M Shively; Margaret J McMillin; Joshua D Smith; Emily H Turner; Mark J Stephan; Lihadh I Al-Gazali; Jozef L Hertecant; David Chitayat; Sheila Unger; Daniel H Cohn; Deborah Krakow; James M Swanson; Elaine M Faustman; Jay Shendure; Deborah A Nickerson; Michael J Bamshad
Journal:  Am J Hum Genet       Date:  2012-12-27       Impact factor: 11.025

Review 4.  Phosphoinositides: Key modulators of energy metabolism.

Authors:  Dave Bridges; Alan R Saltiel
Journal:  Biochim Biophys Acta       Date:  2014-11-20

Review 5.  Discovery and development of small molecule SHIP phosphatase modulators.

Authors:  William G Kerr; John D Chisholm; Dennis R Viernes; Lydia B Choi
Journal:  Med Res Rev       Date:  2013-12-02       Impact factor: 12.944

6.  Structural basis for interdomain communication in SHIP2 providing high phosphatase activity.

Authors:  Johanne Le Coq; Marta Camacho-Artacho; José Vicente Velázquez; Clara M Santiveri; Luis Heredia Gallego; Ramón Campos-Olivas; Nicole Dölker; Daniel Lietha
Journal:  Elife       Date:  2017-08-09       Impact factor: 8.140

Review 7.  SHIPping out diabetes-Metformin, an old friend among new SHIP2 inhibitors.

Authors:  Sanna Lehtonen
Journal:  Acta Physiol (Oxf)       Date:  2019-08-12       Impact factor: 6.311

8.  The 5-Phosphatase SHIP2 Promotes Neutrophil Chemotaxis and Recruitment.

Authors:  Melina Michael; Barry McCormick; Karen E Anderson; Utsa Karmakar; Matthieu Vermeren; Stéphane Schurmans; Augustin Amour; Sonja Vermeren
Journal:  Front Immunol       Date:  2021-04-19       Impact factor: 7.561

9.  Ebselen enhances insulin sensitivity and decreases oxidative stress by inhibiting SHIP2 and protects from inflammation in diabetic mice.

Authors:  Zydrune Polianskyte-Prause; Tuomas A Tolvanen; Sonja Lindfors; Kanta Kon; Laura C Hautala; Hong Wang; Tsutomu Wada; Hiroshi Tsuneki; Toshiyasu Sasaoka; Sanna Lehtonen
Journal:  Int J Biol Sci       Date:  2022-02-14       Impact factor: 6.580

10.  Long-term p110α PI3K inactivation exerts a beneficial effect on metabolism.

Authors:  Lazaros C Foukas; Benoit Bilanges; Lucia Bettedi; Wayne Pearce; Khaled Ali; Sara Sancho; Dominic J Withers; Bart Vanhaesebroeck
Journal:  EMBO Mol Med       Date:  2013-03-11       Impact factor: 12.137

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.